Results 11 to 20 of about 3,346,248 (200)

Incomplete pregnancy and risk of ovarian cancer: Results from two Australian case–control studies and systematic review [PDF]

open access: yes, 2009
Although full-term pregnancies reduce the risk of ovarian cancer, it has not been conclusively established whether incomplete pregnancies also influence risk.
Dick, Marie-Louise B.   +12 more
core   +1 more source

Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies.

open access: yesPLoS Medicine, 2012
BackgroundOnly about half the studies that have collected information on the relevance of women's height and body mass index to their risk of developing ovarian cancer have published their results, and findings are inconsistent.
Collaborative Group on Epidemiological Studies of Ovarian Cancer
doaj   +1 more source

Targeted anti-vascular therapies for ovarian cancer: current evidence [PDF]

open access: yes, 2013
Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only 36%.
Mcneish, I.   +27 more
core   +1 more source

Maternal pelvic size not predictive of daughter's breast cancer or ovarian cancer in a large Swedish cohort. [PDF]

open access: yes, 2009
Recent studies from Finland reported that maternal pelvic size predicted daughters' breast and ovarian cancer, possibly because maternal pelvic size is a marker for in utero hormone exposure.
Goodman, Anna   +8 more
core   +1 more source

DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance

open access: yesNeoplasia: An International Journal for Oncology Research, 2011
Clinical resistance to chemotherapy is a frequent event in cancer treatment and is closely linked to poor outcome. High-grade serous (HGS) ovarian cancer is characterized by p53 mutation and high levels of genomic instability. Treatment includes platinum-
Euan A. Stronach   +6 more
doaj   +1 more source

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk [PDF]

open access: yes, 2013
BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with breast and 1,839 were
Side, Lucy E.,   +999 more
core   +1 more source

Clinical Evaluation of BRCA1/2 Mutation in Mexican Ovarian Cancer Patients

open access: yesTranslational Oncology, 2020
Ovarian cancer (OC) is an important cause of gynecologic cancer-related deaths. In Mexico, around 4700 new cases of OC are diagnosed per year and it represents the second cause of gynecological cancer mortality with more than 2700 deaths.
Dolores Gallardo-Rincón   +11 more
doaj   +1 more source

Investigating the potential for expediting diagnosis of ovarian cancer via prompt symptom recognition & "targeted screening" [PDF]

open access: yes, 2009
PhDThis thesis explores the potential for using symptoms as a tool to bring forward the diagnosis of ovarian cancer. Current evidence supports the existence of prediagnostic symptoms, however symptom lead time has yet to be adequately quantified ...
Lim, Anita Wey Wey
core   +2 more sources

Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification

open access: yesnpj Precision Oncology, 2021
Endometrioid ovarian carcinoma (EnOC) is an under-investigated ovarian cancer type. Recent studies have described disease subtypes defined by genomics and hormone receptor expression patterns; here, we determine the relationship between these subtyping ...
Robert L. Hollis   +12 more
doaj   +1 more source

Advocacy in Action: Leveraging the Power of Patient Voices to Impact Ovarian Cancer Outcomes in Canada

open access: yesCurrent Oncology, 2022
Prior to 1997, ovarian cancer (OC) was a ‘poor target’ for patient advocacy. At that time, there were only three OC researchers in Canada, little information available for women diagnosed, and no community of survivors existed.
Elisabeth Baugh   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy